| Literature DB >> 32863876 |
Dayahindara Veitía1, Juan Liuzzi2, Maira Ávila1, Idamelys Rodriguez3, Felix Toro3, María Correnti1.
Abstract
INTRODUCTION: Head and neck cancers (NHCs) are of multifaceted origins, and tobacco and alcohol are the primary risk factors. Currently, other factors associated with the genesis of these tumours are being considered, among these viral infections, especially human papillomavirus (HPV) infection.Entities:
Keywords: HPV; head and neck; integration; survival; viral load
Year: 2020 PMID: 32863876 PMCID: PMC7434508 DOI: 10.3332/ecancer.2020.1082
Source DB: PubMed Journal: Ecancermedicalscience ISSN: 1754-6605
Sequences of the initiators used in the real-time PCR to quantify the viral genome.
| Initiator name | Sequence 5ʹ----› 3ʹ |
|---|---|
| HPV-16 E2F primer | ACGACTATCCAGCGACCAAGAT |
| HPV-16 E2R primer | CCACTGAGTCTCTGTGCAACAAC |
| HPV-16 E6F primer | GCACAGAGCTGCAAACAACTATACA |
| HPV-16 E6R primer | TCCCGAAAAGCAAAGTCATATACC |
| GP5+ | TTTGTTACTGTGGTAGATACTAC |
| GP6+ | CTTATACTAAATGTCAAATAAAAAG |
| PC04 | CAA CTT CAT CCA CGT TCA CC |
| GH20 | GAA GAG CCA AGG ACA GGT AC |
Characteristics of the samples in the study.
| Sample characteristics | Percentage of patients (%) | |
|---|---|---|
| Female | 31.25 (25/80) | 0.001 |
| Male | 68.75 (55/80) | |
| Yes | 73.75 (59/80) | 0.000 |
| No | 26.25 (21/80) | |
| Yes | 70 (56/80) | 0.000 |
| No | 30 (24/80) | |
| Oral cavity | 33.8 (27/80) | 0.000 |
| Larynx | 30 (24/80) | |
| Oropharynx | 22.50 (18/80) | |
| Paranasal sinuses | 5 (4/80) | |
| Nasopharynx | 3.80 (3/80) | |
| Hypopharynx | 2.50 (2/80) | |
| Nasal cavities | 2.50 (2/80) | |
| T1 | 8.80 (7/80) | |
| T2 | 21.2 (17/80) | |
| T3 | 30 (24/80) | |
| T4 | 40 (32/80) | |
| G1 | 20 (16/80) | 0.03 |
| G2 | 43.75 (35/80) | |
| G3 | 36.25 (29/80) | |
| EI | 6.30 (5/80) | 0.000 |
| EII | 12.50 (10/80) | |
| EIII | 27.50 (22/80) | |
| EIV | 53.8 (43/80) | |
HPV infection in patients with HNSCC.
| Detection of HPV infection | Percentage of patients | |
|---|---|---|
| Positive | 66 (53/80) | 0.004 |
| Negative | 34(27/80) | |
| 16 | 52.8 (28/53) | 0.000 |
| Other LR genotypes | 20.7 (11/53) | |
| Other HR genotypes | 26.4 (14/53) | |
| Oral cavity | 34 (18/53) | 0.606 |
| Larynx | 28(15/53) | |
| Oropharynx | 23(12/53) | |
| Paranasal sinuses | 8 (4/53) | |
| Hypopharynx | 4(2/53) | |
| Nasopharynx | 4(2/53) | |
| EI | 4 (2/53) | 0.312 |
| EII | 15 (8/53) | |
| EIII | 26(14/53) | |
| EIV | 55(29/53) | |
Other HR genotypes: Other high-risk genotypes
Other LR genotypes: Other low-risk genotypes.
HPV load and physical status in patients with HNSCC.
| Tumour site | Clinical data | Viral load and physical status of | |||||
|---|---|---|---|---|---|---|---|
| Oropharynx | 4 | 2b | 16, 18 | ND | 0 | No E2 | Integrated |
| Larynx | 3 | 0 | 16 | 4 | 0 | No E2 | Integrated |
| Larynx | 4 | 3 | 16 | 4 | 0 | No E2 | Integrated |
| Oral cavity | 4 | 0 | 16 | 4 | 0 | No E2 | Integrated |
| Oropharynx | 2 | 0 | 16 | 16 | 5 | 0.8 | Mixed |
| Oral cavity | 3 | 0 | 16 | 9 | 0 | No E2 | Integrated |
| Oropharynx | 4 | 3 | 16 | 20 | 4 | 1.75 | Episomal |
| Oral cavity | 2 | 0 | 16,18,31 | ND | 0 | No E2 No E6 | NA |
| Oral cavity | 4 | 2b | 16 | 3 | 0 | No E2 | Integrated |
| Larynx | 2 | 0 | 6,16 | 5 | 0 | No E2 | Integrated |
| Oropharynx | 3 | 0 | 16 | 2 | 0 | No E2 | Integrated |
| Larynx | 4 | 0 | 6,11 and 16 | 3 | 0 | No E2 | Integrated |
| Larynx | 2 | 0 | 6,11 and 16 | 8 | 0 | No E2 | Integrated |
| Oropharynx | 4 | 0 | 11,61 | 10 | 7 | 0.5 | Mixed |
| Oral cavity | 2 | 3 | 6,11 and 16 | ND | 0 | No E2 No E6 | NA |
| Oral cavity | 4 | 2b | 11, 16 | 3 | 0 | No E2 | Integrated |
| Oral cavity | 2 | 1 | 6,11 and 16 | 3 | 0 | No E2 | Integrated |
| Hypopharynx | 4 | 2c | 6,11 and 16 | 3 | 0 | No E2 | Integrated |
| Larynx | 3 | 3 | 6,11 and 16 | 4 | 0 | No E2 | Integrated |
| Larynx | 3 | 0 | 6,11 and 16 | 3 | 0 | No E2 | Integrated |
| Oral cavity | 2 | 0 | 6,11,16,18 | ND | 0 | No E2 No E6 | NA |
| Oral cavity | 3 | 0 | 6,11 and 16 | ND | 0 | No E2 No E6 | NA |
| Nasopharynx | 4 | 3 | 11, 16, 51 | ND | 0 | No E2 No E6 | NA |
| Oral cavity | 1 | 0 | 6,11,16,53 | 4 | 0 | No E2 | Integrated |
| Larynx | 2 | 0 | 6,11 and 16 | 2 | 0 | No E2 | Integrated |
| Hypopharynx | 2 | 3 | 6,11,16,31 | ND | 0 | No E2 No E6 | NA |
| Oropharynx | 2 | 2b | 6,11,16,31 | 3 | 0 | No E2 | Integrated |
| Larynx | 2 | 0 | 6,16,18,31 | 3 | 0 | No E2 | Integrated |
| Oral cavity | 2 | 1 | 6,16,18,31 | 4 | 0 | No E2 No E6 | NA |
| Nasopharynx | 3 | 0 | 6,11,16,31 | ND | 0 | No E2 No E6 | NA |
Not determined.
Not applicable.
Figure 1.Survival curves of patients with squamous cell carcinoma in the head and neck. A) Patients with HNSCC in relation to tobacco consumption (n = 80; p = 0.187). B) Patients with HNSCC in relation to tumour stage (n = 80; p = 0.087). C) Patients with HNSCC in relation to gender (n = 80. p = 0.171).
Figure 2.Analysis of survival of patients with squamous cell carcinoma in the head and neck in relation to: A) HPV genome presence (without distinguishing genotype) (n = 53; p > 0.05). B) Integration of the viral genome into the host cell genome (n = 28. p > 0.05).